MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).

Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible?

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.

Non-viral gene therapies may hold potential to overcome some safety, pricing and manufacturing hurdles linked to viral alternatives.

Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies targeting wider patient groups.

UCB’s Candid acquisition marks its second foray into the TCE space – closely following a $1.1bn licensing deal with TCE specialist, Antengene.

Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.

LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Arrowhead Pharmaceuticals has received approval from the Australian TGA for Redemplo to treat familial chylomicronemia syndrome.

BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.

Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s.

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.